Cargando…
Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
Gut microbiota dysregulation plays a key role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) through its metabolites. Therefore, the restoration of the gut microbiota and supplementation with commensal bacterial metabolites can be of therapeutic benefit against the disease. In this...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432372/ https://www.ncbi.nlm.nih.gov/pubmed/32717871 http://dx.doi.org/10.3390/ijms21155214 |
_version_ | 1783571783071301632 |
---|---|
author | Chen, Jiezhong Vitetta, Luis |
author_facet | Chen, Jiezhong Vitetta, Luis |
author_sort | Chen, Jiezhong |
collection | PubMed |
description | Gut microbiota dysregulation plays a key role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) through its metabolites. Therefore, the restoration of the gut microbiota and supplementation with commensal bacterial metabolites can be of therapeutic benefit against the disease. In this review, we summarize the roles of various bacterial metabolites in the pathogenesis of NAFLD and their therapeutic implications. The gut microbiota dysregulation is a feature of NAFLD, and the signatures of gut microbiota are associated with the severity of the disease through altered bacterial metabolites. Disturbance of bile acid metabolism leads to underactivation of bile acid receptors FXR and TGR5, causal for decreased energy expenditure, increased lipogenesis, increased bile acid synthesis and increased macrophage activity. Decreased production of butyrate results in increased intestinal inflammation, increased gut permeability, endotoxemia and systemic inflammation. Dysregulation of amino acids and choline also contributes to lipid accumulation and to a chronic inflammatory status. In some NAFLD patients, overproduction of ethanol produced by bacteria is responsible for hepatic inflammation. Many approaches including probiotics, prebiotics, synbiotics, faecal microbiome transplantation and a fasting-mimicking diet have been applied to restore the gut microbiota for the improvement of NAFLD. |
format | Online Article Text |
id | pubmed-7432372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74323722020-08-24 Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications Chen, Jiezhong Vitetta, Luis Int J Mol Sci Review Gut microbiota dysregulation plays a key role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) through its metabolites. Therefore, the restoration of the gut microbiota and supplementation with commensal bacterial metabolites can be of therapeutic benefit against the disease. In this review, we summarize the roles of various bacterial metabolites in the pathogenesis of NAFLD and their therapeutic implications. The gut microbiota dysregulation is a feature of NAFLD, and the signatures of gut microbiota are associated with the severity of the disease through altered bacterial metabolites. Disturbance of bile acid metabolism leads to underactivation of bile acid receptors FXR and TGR5, causal for decreased energy expenditure, increased lipogenesis, increased bile acid synthesis and increased macrophage activity. Decreased production of butyrate results in increased intestinal inflammation, increased gut permeability, endotoxemia and systemic inflammation. Dysregulation of amino acids and choline also contributes to lipid accumulation and to a chronic inflammatory status. In some NAFLD patients, overproduction of ethanol produced by bacteria is responsible for hepatic inflammation. Many approaches including probiotics, prebiotics, synbiotics, faecal microbiome transplantation and a fasting-mimicking diet have been applied to restore the gut microbiota for the improvement of NAFLD. MDPI 2020-07-23 /pmc/articles/PMC7432372/ /pubmed/32717871 http://dx.doi.org/10.3390/ijms21155214 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chen, Jiezhong Vitetta, Luis Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications |
title | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications |
title_full | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications |
title_fullStr | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications |
title_full_unstemmed | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications |
title_short | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications |
title_sort | gut microbiota metabolites in nafld pathogenesis and therapeutic implications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432372/ https://www.ncbi.nlm.nih.gov/pubmed/32717871 http://dx.doi.org/10.3390/ijms21155214 |
work_keys_str_mv | AT chenjiezhong gutmicrobiotametabolitesinnafldpathogenesisandtherapeuticimplications AT vitettaluis gutmicrobiotametabolitesinnafldpathogenesisandtherapeuticimplications |